Successful treatment of cardiomyopathy due to very long-chain Acyl-CoA dehydrogenase deficiency: First case report from Oman with literature review

Sharef Waadallah Sharef, Khalfan Al-Senaidi, Surendra Nath Joshi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Very long-chain acyl-CoA dehydrogenase deficiency (MIM 201475) is a severe defect of mitochondrial energy production from oxidation of very long-chain fatty acids. This inherited metabolic disorder often presents in early neonatal period with episodes of symptomatic hypoglycemia usually responding well to intravenous glucose infusion. These babies are often discharged without establishment of diagnosis but return by 2-5 months of age with severe and progressive cardiac failure due to hypertrophic cardiomyopathy with or without hepatic failure and steatosis. An early diagnosis and treatment with high concentration medium chain triglycerides based feeding formula can be life saving in such patients. Here, we report the first diagnosed and treated case of Very long-chain acyl-CoA dehydrogenase deficiency in Oman. This infant developed heart failure with left ventricular dilation, hypertrophy and pericardial effusion at the age of 7 weeks. Prompt diagnosis and subsequent intervention with medium chain triglycerides-based formula resulted in a reversal of severe clinical symptoms with significant improvement of cardiac status. This treatment also ensured normal growth and neurodevelopment. It is stressed that the disease must be recognized by the pediatricians and cardiologists since the disease can be identified by Tandem Mass Spectrometry; therefore, it should be considered to be included in expanded newborn screening program, allowing early diagnosis and intervention in order to ensure better outcome and prevent complications.

Original languageEnglish
Pages (from-to)354-356
Number of pages3
JournalOman Medical Journal
Volume28
Issue number5
DOIs
Publication statusPublished - 2013

Fingerprint

Oman
Cardiomyopathies
Early Diagnosis
Triglycerides
Heart Failure
Pericardial Effusion
Hypertrophic Cardiomyopathy
Liver Failure
Left Ventricular Hypertrophy
Tandem Mass Spectrometry
Hypoglycemia
Intravenous Infusions
Dilatation
Fatty Acids
Newborn Infant
Glucose
Therapeutics
Growth
VLCAD deficiency
Cardiologists

Keywords

  • Cardiomyopathy
  • Fatty acid oxidation defect
  • Medium chain triglycerides (MCT) based formula
  • Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Successful treatment of cardiomyopathy due to very long-chain Acyl-CoA dehydrogenase deficiency : First case report from Oman with literature review. / Sharef, Sharef Waadallah; Al-Senaidi, Khalfan; Joshi, Surendra Nath.

In: Oman Medical Journal, Vol. 28, No. 5, 2013, p. 354-356.

Research output: Contribution to journalArticle

@article{9a845926d72d480b96e6ef92df4f05e4,
title = "Successful treatment of cardiomyopathy due to very long-chain Acyl-CoA dehydrogenase deficiency: First case report from Oman with literature review",
abstract = "Very long-chain acyl-CoA dehydrogenase deficiency (MIM 201475) is a severe defect of mitochondrial energy production from oxidation of very long-chain fatty acids. This inherited metabolic disorder often presents in early neonatal period with episodes of symptomatic hypoglycemia usually responding well to intravenous glucose infusion. These babies are often discharged without establishment of diagnosis but return by 2-5 months of age with severe and progressive cardiac failure due to hypertrophic cardiomyopathy with or without hepatic failure and steatosis. An early diagnosis and treatment with high concentration medium chain triglycerides based feeding formula can be life saving in such patients. Here, we report the first diagnosed and treated case of Very long-chain acyl-CoA dehydrogenase deficiency in Oman. This infant developed heart failure with left ventricular dilation, hypertrophy and pericardial effusion at the age of 7 weeks. Prompt diagnosis and subsequent intervention with medium chain triglycerides-based formula resulted in a reversal of severe clinical symptoms with significant improvement of cardiac status. This treatment also ensured normal growth and neurodevelopment. It is stressed that the disease must be recognized by the pediatricians and cardiologists since the disease can be identified by Tandem Mass Spectrometry; therefore, it should be considered to be included in expanded newborn screening program, allowing early diagnosis and intervention in order to ensure better outcome and prevent complications.",
keywords = "Cardiomyopathy, Fatty acid oxidation defect, Medium chain triglycerides (MCT) based formula, Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency",
author = "Sharef, {Sharef Waadallah} and Khalfan Al-Senaidi and Joshi, {Surendra Nath}",
year = "2013",
doi = "10.5001/omj.2013.101",
language = "English",
volume = "28",
pages = "354--356",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "5",

}

TY - JOUR

T1 - Successful treatment of cardiomyopathy due to very long-chain Acyl-CoA dehydrogenase deficiency

T2 - First case report from Oman with literature review

AU - Sharef, Sharef Waadallah

AU - Al-Senaidi, Khalfan

AU - Joshi, Surendra Nath

PY - 2013

Y1 - 2013

N2 - Very long-chain acyl-CoA dehydrogenase deficiency (MIM 201475) is a severe defect of mitochondrial energy production from oxidation of very long-chain fatty acids. This inherited metabolic disorder often presents in early neonatal period with episodes of symptomatic hypoglycemia usually responding well to intravenous glucose infusion. These babies are often discharged without establishment of diagnosis but return by 2-5 months of age with severe and progressive cardiac failure due to hypertrophic cardiomyopathy with or without hepatic failure and steatosis. An early diagnosis and treatment with high concentration medium chain triglycerides based feeding formula can be life saving in such patients. Here, we report the first diagnosed and treated case of Very long-chain acyl-CoA dehydrogenase deficiency in Oman. This infant developed heart failure with left ventricular dilation, hypertrophy and pericardial effusion at the age of 7 weeks. Prompt diagnosis and subsequent intervention with medium chain triglycerides-based formula resulted in a reversal of severe clinical symptoms with significant improvement of cardiac status. This treatment also ensured normal growth and neurodevelopment. It is stressed that the disease must be recognized by the pediatricians and cardiologists since the disease can be identified by Tandem Mass Spectrometry; therefore, it should be considered to be included in expanded newborn screening program, allowing early diagnosis and intervention in order to ensure better outcome and prevent complications.

AB - Very long-chain acyl-CoA dehydrogenase deficiency (MIM 201475) is a severe defect of mitochondrial energy production from oxidation of very long-chain fatty acids. This inherited metabolic disorder often presents in early neonatal period with episodes of symptomatic hypoglycemia usually responding well to intravenous glucose infusion. These babies are often discharged without establishment of diagnosis but return by 2-5 months of age with severe and progressive cardiac failure due to hypertrophic cardiomyopathy with or without hepatic failure and steatosis. An early diagnosis and treatment with high concentration medium chain triglycerides based feeding formula can be life saving in such patients. Here, we report the first diagnosed and treated case of Very long-chain acyl-CoA dehydrogenase deficiency in Oman. This infant developed heart failure with left ventricular dilation, hypertrophy and pericardial effusion at the age of 7 weeks. Prompt diagnosis and subsequent intervention with medium chain triglycerides-based formula resulted in a reversal of severe clinical symptoms with significant improvement of cardiac status. This treatment also ensured normal growth and neurodevelopment. It is stressed that the disease must be recognized by the pediatricians and cardiologists since the disease can be identified by Tandem Mass Spectrometry; therefore, it should be considered to be included in expanded newborn screening program, allowing early diagnosis and intervention in order to ensure better outcome and prevent complications.

KW - Cardiomyopathy

KW - Fatty acid oxidation defect

KW - Medium chain triglycerides (MCT) based formula

KW - Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency

UR - http://www.scopus.com/inward/record.url?scp=84884195237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884195237&partnerID=8YFLogxK

U2 - 10.5001/omj.2013.101

DO - 10.5001/omj.2013.101

M3 - Article

C2 - 24044064

AN - SCOPUS:84884195237

VL - 28

SP - 354

EP - 356

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 5

ER -